blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2407466

EP2407466 - PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.11.2016
Database last updated on 05.10.2024
Most recent event   Tooltip29.06.2018Change - lapse in a contracting state
Updated state(s): MT		published on 01.08.2018  [2018/31]
Applicant(s)For all designated states
Taiho Pharmaceutical Co., Ltd.
1-27 Kandanishiki-cho
Chiyoda-ku, Tokyo 1018444 / JP
[2012/03]
Inventor(s)01 / URADE, Yoshihiro
c/o OSAKA BIOSCIENCE INSTITUTE
6-2-4, Furuedai
Suita-shi Osaka 565-0874 / JP
02 / KITADE, Makoto
c/o TAIHO PHARMACEUTICAL CO. LTD.
1-27, Misugidai
Hanno-shi Saitama 357-8527 / JP
03 / SHIGENO, Kazuhiko
c/o TAIHO PHARMACEUTICAL CO. LTD.
1-27, Misugidai
Hanno-shi Saitama 357-8527 / JP
04 / YAMANE, Keiko
c/o TAIHO PHARMACEUTICAL CO. LTD.
1-27, Misugidai
Hanno-shi Saitama 357-8527 / JP
05 / TANAKA, Katsunao
c/o TAIHO PHARMACEUTICAL CO. LTD.
1-27, Misugidai
Hanno-shi Saitama 357-8527 / JP
 [2012/03]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2016/02]
Former [2012/03]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date10750777.408.03.2010
[2016/02]
WO2010JP53760
Priority number, dateJP2009005572109.03.2009         Original published format: JP 2009055721
[2012/03]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010104024
Date:16.09.2010
Language:JA
[2010/37]
Type: A1 Application with search report 
No.:EP2407466
Date:18.01.2012
Language:EN
[2012/03]
Type: B1 Patent specification 
No.:EP2407466
Date:13.01.2016
Language:EN
[2016/02]
Search report(s)International search report - published on:JP16.09.2010
(Supplementary) European search report - dispatched on:EP07.08.2012
ClassificationIPC:C07D401/12, A61K31/496, A61K31/5377, A61P1/04, A61P3/04, A61P7/04, A61P9/00, A61P11/00, A61P11/06, A61P15/00, A61P15/06, A61P15/08, A61P17/00, A61P17/04, A61P17/06, A61P17/10, A61P19/02, A61P21/00, A61P21/04, A61P25/00
[2012/03]
CPC:
C07D401/14 (EP,KR,US); A61K31/496 (EP,KR,US); A61K31/5377 (EP,US);
A61P1/04 (EP); A61P11/00 (EP); A61P11/02 (EP);
A61P11/06 (EP); A61P15/00 (EP); A61P15/06 (EP);
A61P15/08 (EP); A61P15/10 (EP); A61P17/00 (EP);
A61P17/04 (EP); A61P17/06 (EP); A61P17/10 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P21/02 (EP);
A61P21/04 (EP); A61P25/00 (EP); A61P25/04 (EP);
A61P25/20 (EP); A61P25/28 (EP); A61P27/02 (EP);
A61P27/14 (EP); A61P27/16 (EP); A61P29/00 (EP);
A61P3/04 (EP); A61P35/00 (EP); A61P35/04 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P7/04 (EP); A61P9/00 (EP); A61P9/10 (EP);
C07D207/34 (EP,US); C07D213/81 (EP,US); C07D277/82 (EP,US);
C07D401/12 (EP,US); C07D403/12 (EP,US); C07D403/14 (EP,US);
C07D405/12 (EP,US); C07D409/12 (EP,US); C07D413/12 (EP,US);
C07D413/14 (EP,KR,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/03]
Extension statesALNot yet paid
BANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:PIPERAZINVERBINDUNG ZUR PROSTAGLANDIN-D-SYNTHASE-HEMMUNG[2012/03]
English:PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE[2012/03]
French:COMPOSÉ DE PIPÉRAZINE CAPABLE D'INHIBER LA PROSTAGLANDINE D SYNTHASE[2012/03]
Entry into regional phase05.10.2011Translation filed 
05.10.2011National basic fee paid 
05.10.2011Search fee paid 
05.10.2011Designation fee(s) paid 
05.10.2011Examination fee paid 
Examination procedure05.10.2011Examination requested  [2012/03]
29.01.2013Amendment by applicant (claims and/or description)
16.07.2015Communication of intention to grant the patent
19.11.2015Fee for grant paid
19.11.2015Fee for publishing/printing paid
19.11.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.07.2015
Opposition(s)14.10.2016No opposition filed within time limit [2016/51]
Fees paidRenewal fee
21.03.2012Renewal fee patent year 03
22.03.2013Renewal fee patent year 04
21.03.2014Renewal fee patent year 05
23.03.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY13.01.2016
EE13.01.2016
HR13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
MK13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
LU08.03.2016
MT31.03.2016
BG13.04.2016
[2018/31]
Former [2018/28]CY13.01.2016
EE13.01.2016
HR13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
MK13.01.2016
MT13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
LU08.03.2016
BG13.04.2016
Former [2017/47]EE13.01.2016
HR13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
MT13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
LU08.03.2016
BG13.04.2016
Former [2017/15]EE13.01.2016
HR13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
LU08.03.2016
BG13.04.2016
Former [2016/50]EE13.01.2016
HR13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
SK13.01.2016
SM13.01.2016
LU08.03.2016
Former [2016/49]EE13.01.2016
HR13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
LU08.03.2016
Former [2016/47]HR13.01.2016
LT13.01.2016
LV13.01.2016
LU08.03.2016
Former [2016/39]HR13.01.2016
LT13.01.2016
LV13.01.2016
Former [2016/36]HR13.01.2016
LT13.01.2016
Former [2016/35]HR13.01.2016
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[A]JP2001288160  (SHIONOGI & CO);
 [A]JP2006508077  (MILLENNIUM PHARM INC.);
 [A]WO2008122787  (EVOTEC AG [DE], et al)
by applicantWO9907672
 WO2007007778
 WO2007041634
 WO2007054623
 WO2008023720
 WO2008122787
    - J. IMMUNOL., (1982), vol. 129, pages 1627 - 1631
    - N. ENG. J. MED., (1986), vol. 315, pages 800 - 804
    - N. ENG. J. MED., (1984), vol. 311, pages 209 - 213
    - ARCH. OTOLARYNGOL HEAD NECK SURG., (2007), vol. 133, pages 693 - 700
    - ACTA NEUROPATHOL., (2002), vol. 104, pages 377 - 384
    - AIR. J PATHOL., (2009), vol. 174, no. 5, pages 1735 - 1744
    - IYAKUHIN NO KAIHATSU, Development of Pharmaceuticals, HIROKAWA PUBLISHING, (1990), vol. 7, pages 163 - 198
    - URADE, Y. ET AL., J. BIOL. CHEM., (1987), vol. 262, pages 3820 - 3825
    - MUSCLE NERVE., (2007), vol. 35, pages 43 - 48
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.